Cost-effectiveness analysis of integrating screening and treatment of selected non-communicable diseases into HIV/AIDS treatment in Uganda.

David SandoAlexander KintuSamson OkelloPeter Chris KawungeziDavid GuwatuddeGerald MutungiWinnie MuyindikeNicolas A MenziesGoodarz DanaeiStéphane Verguet

Published in: Journal of the International AIDS Society (2021)

Providing services for hypertension, DM and high cholesterol for Ugandan ART patients would reduce the overall CVD risk among these patients; it would amount to about 2.4% of national HIV/AIDS expenditure, and would present a cost-effectiveness comparable to other standalone interventions to address NCDs in low- and middle-income country settings.

Keyphrases

hiv aids
end stage renal disease
antiretroviral therapy
newly diagnosed
chronic kidney disease
physical activity
prognostic factors
blood pressure
type diabetes
hiv infected
hepatitis c virus
metabolic syndrome
patient reported
replacement therapy
smoking cessation